A Cost‐Benefit Analysis of Government Compensation of Kidney Donors
dc.contributor.author | Held, P. J. | |
dc.contributor.author | McCormick, F. | |
dc.contributor.author | Ojo, A. | |
dc.contributor.author | Roberts, J. P. | |
dc.date.accessioned | 2016-10-17T21:18:29Z | |
dc.date.available | 2017-05-02T15:09:13Z | en |
dc.date.issued | 2016-03 | |
dc.identifier.citation | Held, P. J.; McCormick, F.; Ojo, A.; Roberts, J. P. (2016). "A Cost‐Benefit Analysis of Government Compensation of Kidney Donors." American Journal of Transplantation (3): 877-885. | |
dc.identifier.issn | 1600-6135 | |
dc.identifier.issn | 1600-6143 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/134169 | |
dc.description.abstract | From 5000 to 10 000 kidney patients die prematurely in the United States each year, and about 100 000 more suffer the debilitating effects of dialysis, because of a shortage of transplant kidneys. To reduce this shortage, many advocate having the government compensate kidney donors. This paper presents a comprehensive cost‐benefit analysis of such a change. It considers not only the substantial savings to society because kidney recipients would no longer need expensive dialysis treatments—$1.45 million per kidney recipient—but also estimates the monetary value of the longer and healthier lives that kidney recipients enjoy—about $1.3 million per recipient. These numbers dwarf the proposed $45 000‐per‐kidney compensation that might be needed to end the kidney shortage and eliminate the kidney transplant waiting list. From the viewpoint of society, the net benefit from saving thousands of lives each year and reducing the suffering of 100 000 more receiving dialysis would be about $46 billion per year, with the benefits exceeding the costs by a factor of 3. In addition, it would save taxpayers about $12 billion each year.This analysis of a government program to compensate kidney donors indicates the monetary value of saving thousands of lives each year and reducing the suffering of a hundred thousand more on dialysis would be about $46 billion per year, and would save taxpayers about $12 billion a year. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | American Enterprise Institute for Public Policy Research | |
dc.subject.other | kidney transplantation: living donor | |
dc.subject.other | organ allocation | |
dc.subject.other | clinical research/practice | |
dc.subject.other | health services and outcomes research | |
dc.subject.other | kidney transplantation/nephrology | |
dc.subject.other | law/legislation | |
dc.subject.other | organ transplantation in general | |
dc.subject.other | dialysis | |
dc.subject.other | donors and donation: living | |
dc.subject.other | quality of life (QOL) | |
dc.title | A Cost‐Benefit Analysis of Government Compensation of Kidney Donors | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Medicine (General) | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/134169/1/ajt13490.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/134169/2/ajt13490-sup-0001-Suppmat.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/134169/3/ajt13490_am.pdf | |
dc.identifier.doi | 10.1111/ajt.13490 | |
dc.identifier.source | American Journal of Transplantation | |
dc.identifier.citedreference | Hornberger JC, Best JH, Garrison LP Jr. Cost‐effectiveness of repeat medical procedures: kidney transplantation as an example. Med Decis Making 1997; 17: 363 – 372. | |
dc.identifier.citedreference | Hall MJ, Levant S, DeFrances CJ. Trends in inpatient hospital deaths: National Hospital Discharge Survey, 2000–2010. NCHS Data Brief No. 118, March 2013. | |
dc.identifier.citedreference | Fresenius Medical Care AG & Co. Form 20‐F Securities and Exchange Commission, Washington, D.C. 20549 and 2012 continuity corporate report. Bad Homburg, Germany: Fresenius Medical Care AG & Co; 2012. | |
dc.identifier.citedreference | Ghods AJ, Savaj S. Iranian model of paid and regulated living‐unrelated kidney donation. Clin J Am Soc Nephrol 2006; 1: 1136 – 1145. | |
dc.identifier.citedreference | Salomon DR, Langnas AN, Reed AI, et al; for the AST/ASTS Incentives Workshop Group (IWG). Meeting report, AST/ASTS Workshop on Increasing Organ Donation in the United States: creating an “arc of change” from removing disincentives to testing incentives. Am J Ttransplant 2015; 5: 1600 – 6143. | |
dc.identifier.citedreference | Public Law 1984 Oct 19. Public Law 98‐507 NOTA. | |
dc.identifier.citedreference | Huang ES, Thakur N, Meltzer DO. The cost‐effectiveness of renal transplantation. In Satel S, editor. When altruism isn’t enough: the case for compensating kidney donors. Washington, DC: American Enterprise Institute for Public Policy Research; 2008. | |
dc.identifier.citedreference | Beard TR, Kaserman DL, Osterkamp R. The global organ shortage. Stanford University Press; 2013. | |
dc.identifier.citedreference | Becker GS, Elías JJ. Introducing incentives in the market for live and cadaveric organ donations. Journal of Economic Perspectives 2007; 21: 3 – 24. | |
dc.identifier.citedreference | Matas AJ, Schnitzler M. Payment for living donor (vendor) kidneys: a cost‐effectiveness analysis. Am J Transplant 2003; 4: 216 – 221. | |
dc.identifier.citedreference | US Renal Data System. USRDS 2013 annual data report: atlas of chronic kidney disease and end‐stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013. | |
dc.identifier.citedreference | Scientific Registry of Transplant Recipients (SRTR). Annual data report, I. Kidney. Washington, DC: US Department of Health and Human Services, HRSA; 2012. | |
dc.identifier.citedreference | Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertainty 2003; 27: 1, 5 – 76. | |
dc.identifier.citedreference | Schold JD, Srinivas TR, Kayler LK, Meier‐Kriesche HU. The overlapping risk profile between dialysis patients listed and not listed for renal transplantation. Am J Transplant 2008; 8: 58 – 68. | |
dc.identifier.citedreference | Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality‐adjusted life‐year: in search of a standard. Med Decis Making 2000; 20: 332 – 342. | |
dc.identifier.citedreference | Whiting JF; for the Transplant Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation 2000; 70: 1115 – 1121. | |
dc.identifier.citedreference | Tolley G, Kenkel D, Fabian R, editors. Valuing health for policy: an economic approach. Chicago: University of Chicago Press; 1994. | |
dc.identifier.citedreference | Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost‐utility of renal transplantation. Kidney Int 1996; 50: 235 – 242. | |
dc.identifier.citedreference | Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation: a prospective study. Transplantation 1992; 54: 656 – 660. | |
dc.identifier.citedreference | Mahdavi‐Mazdeh M. The Iranian model of living renal transplantation. Kidney Int 2012; 82: 627 – 634. | |
dc.identifier.citedreference | Tanriover B, Stone PW, Mohan S, Cohen DJ, Gaston RS. Future of Medicare immunosuppressive drug coverage of kidney transplant recipients in the United States. Clin J Am Soc Nephrol 2013 April 4. doi: 10.2215/CJN.09440912 | |
dc.identifier.citedreference | Englesbe MJ, Ads Y, Cohn JA, et al. The effects of donor and recipient practices on transplant center finances. Am J Transplant 2008; 8: 586 – 592. | |
dc.identifier.citedreference | Wolfe RA, McCullough KP, Schaubel DE, et al. Calculating life years from transplant (LYFT): methods for kidney and kidney‐pancreas candidates. Am J Transplant 2008; 8 ( Pt 2 ): 997 – 1011. | |
dc.identifier.citedreference | Cook PJ, Krawiec K. A primer on kidney transplantation: anatomy of the shortage. Law Contemp Probl 2014; 77: 16 – 19. | |
dc.identifier.citedreference | Muzaale AD, Massie AB, Wang MC, et al. Risk of end‐stage renal disease following live kidney donation. JAMA 2014; 311: 579 – 586. | |
dc.identifier.citedreference | Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid‐organ transplant in the United States. JAMA Surg 2015; 150: 3. | |
dc.identifier.citedreference | Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 2014; 21: 426 – 433. | |
dc.identifier.citedreference | Meier‐Kriesche HU, Port FK, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311 – 1317. | |
dc.identifier.citedreference | Wetmore JB, Rigler SK, Mahnken JD, Mukhopadhyay P, Shireman TI. Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage ? Nephrol Dialysis Transplant 2010; 25: 198 – 205. | |
dc.identifier.citedreference | Leighton T, Gustafson S, Snyder J, Israni A, Kasiske B. Changes in Medicare coverage after kidney transplant. Am J Transplant 2014; 14 (Suppl 3): 848 – 849. Abstract D2750. | |
dc.identifier.citedreference | Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: Updating the Renal Dialysis Cost‐Effectiveness Standard. Value in Health 2008; 12: 80 – 87. | |
dc.identifier.citedreference | DaVita Health Care Partners Inc. Form 10K filed with the U.S. Security and Exchange Commission for fiscal year ended 12 31 2012. Washington, DC: DaVita Health Care Partners Inc; 2012. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.